Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261548/
https://www.ncbi.nlm.nih.gov/pubmed/28174493
http://dx.doi.org/10.2147/CEOR.S118835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261548/
https://www.ncbi.nlm.nih.gov/pubmed/28174493
http://dx.doi.org/10.2147/CEOR.S118835

Ejemplares similares